search
Back to results

Advent™ Cervical Disc Versus ACDF for Treatment of One Level Degenerative Disc Disease (IDE Study)

Primary Purpose

Cervical Degenerative Disc Disease

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cervical Artificial Disc (Advent™ Cervical Disc)
Hallmark™ Anterior Cervical Plate System
Sponsored by
Orthofix Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cervical Degenerative Disc Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • One cervical spine level between C3 and C7 which requires surgical treatment for intractable cervical radiculopathy and/or myelopathy demonstrated by herniated disc, and/or osteophyte formation leading to nerve root and/or spinal cord compression confirmed by patient history (e.g. neck and/or arm pain), functional and/or neurological deficit (e.g. numbness, weakness, diminished or pathologic reflexes, gait disturbances, etc.) and radiographic studies (e.g. CT, MRI, x-rays, etc.).
  • Unresponsive to conservative care over a period of at least 6 weeks
  • Neck Disability Index score ≥ 15/50 (30%)
  • Willing and able to comply with the requirements of the protocol including follow-up requirements and to sign a study specific informed consent

Exclusion Criteria:

  • More than 1 level requiring surgical treatment for intractable cervical radiculopathy and/or myelopathy.
  • Active local (at the proposed surgical site) or systemic infection
  • Prior anterior neck surgery at any level.
  • Prior posterior cervical spine surgery at the index level except posterior decompressive surgery where the posterior elements are preserved.
  • Currently undergoing treatment for disease of the thoracic or lumbar spine.
  • Axial neck pain as the primary diagnosis, without evidence of neural compression
  • Significant cervical anatomical deformity
  • Any anatomical consideration which in the investigators opinion would make the anterior cervical approach excessively risky or impossible
  • Severe obesity defined as a Body Mass Index (BMI) > 40
  • Instability on AP, lateral neutral or flex/ext images: ≥2mm translation relative to the adjacent segment, and/or ≥ 11 degrees relative to adjacent segments
  • Central disc height ≤ 2mm
  • Advanced spondylosis (i.e. facet joints degeneration, anterior or posterior bridging of the interspace or lack of motion on the pre-operative flexion/extension x-rays)
  • Severe cervical myelopathy as indicated by: Signs and/or symptoms > 6months duration, Nurick's Classification grades IV or V, and/or Myelomalacia as evidence on a MRI
  • Metabolic bone disease such as osteoporosis to a degree that spinal instrumentation is contra-indicated (Males over 55 years of age, females over 50 years of age and/or subjects that in the investigators opinion are medical indicative of osteoporosis (e.g. early menopause, steroid use, etc.) are required to have a DEXA scan; If the DEXA scan is ≤ -2.5t in the spine, the patient must be excluded)
  • Allergy to any component of the device (titanium, polycarbonated polyurethane, polyethylene terephthalate, or ethylene oxide residuals)
  • Chronic steroid or other medication use that may interfere with bony/soft tissue healing
  • History of endocrine or metabolic disorders (e.g. Paget's disease) known to effect bone and mineral metabolism
  • Autoimmune diseases e.g., ankylosing spondylitis, rheumatoid arthritis, etc.
  • Insulin dependent diabetes mellitus
  • Active malignancy
  • Currently pregnant or considering becoming pregnant during the follow-up period
  • Advanced emphysema, Alzheimer's disease or other medical conditions that would interfere with patient self-assessment of function, pain or quality of life
  • Medical condition (e.g. unstable cardiac disease, end-stage cancer) that may result in patient death prior to study completion
  • Chemical dependency (e.g. alcohol or narcotic addiction) problem that may interfere with study requirements
  • Mental incompetence as determined by the Investigator which may effect participation in the study
  • Incarcerated
  • Involved in any current or pending litigation relating to a spinal condition
  • Concurrently participating in any other investigational study
  • Anatomy (e.g. endplate dimensions) at the index level not consistent with the dimensions of the implants available (e.g. based on pre-operative radiographic evaluations and templates in the surgical technique manual).

Sites / Locations

  • University of California Davis
  • Boulder Neurosurgical Associates
  • University of South Florida
  • Spine Institute of Louisiana
  • Brain and Spine Specialist
  • Cooper University Neurological Institute
  • University of Rochester Medical Center
  • Triangle Orthopaedics Associates, P.A.
  • University of Pennsylvania, Department of Neurosurgery
  • Medical University of South Carolina
  • East Tennessee Brain and Spine Center
  • Texas Back Institute
  • The San Antonio Orthopaedic Group

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Advent™ Cervical Disc

Standard care - Control

Arm Description

Cervical artificial disc replacement: Advent™ Cervical Disc

Anterior cervical discectomy and fusion (ACDF) with Hallmark™ Anterior Cervical Plate System

Outcomes

Primary Outcome Measures

Evaluation of Device and/or Procedure Related Adverse Event(s)

Secondary Outcome Measures

Full Information

First Posted
March 10, 2008
Last Updated
February 12, 2014
Sponsor
Orthofix Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00637312
Brief Title
Advent™ Cervical Disc Versus ACDF for Treatment of One Level Degenerative Disc Disease (IDE Study)
Official Title
Clinical Trial Comparing the Blackstone Advent™ Cervical Disc to Anterior Cervical Discectomy and Fusion (ACDF) for the Treatment of One Level Degenerative Disc Disease
Study Type
Interventional

2. Study Status

Record Verification Date
February 2014
Overall Recruitment Status
Terminated
Why Stopped
Greater-than-anticipated rate of revisions
Study Start Date
March 2008 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
February 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Orthofix Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to establish the safety and effectiveness of the Advent™ Cervical Disc compared to Anterior Cervical Discectomy and Fusion (ACDF) in treating degenerative disc disease at a single-level in the cervical spine (from C3 to C7) following cervical discectomy in skeletally mature patients (at least 18 years of age).
Detailed Description
Following surgery study subjects will be evaluated at the following intervals: 6 wks (± 2wks); 3 Months (±2 wks); 6 Month (±1 months); 12 and 24 Month (±2 months) and annually until the last subject enrolled completes their 24 Month follow-up

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Degenerative Disc Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
108 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Advent™ Cervical Disc
Arm Type
Experimental
Arm Description
Cervical artificial disc replacement: Advent™ Cervical Disc
Arm Title
Standard care - Control
Arm Type
Active Comparator
Arm Description
Anterior cervical discectomy and fusion (ACDF) with Hallmark™ Anterior Cervical Plate System
Intervention Type
Device
Intervention Name(s)
Cervical Artificial Disc (Advent™ Cervical Disc)
Other Intervention Name(s)
Advent™ Cervical Disc
Intervention Description
Advent™ Cervical Disc
Intervention Type
Device
Intervention Name(s)
Hallmark™ Anterior Cervical Plate System
Intervention Description
Hallmark™ Anterior Cervical Plate System with AlloQuent Structural Allograft (corticocancellous allograft bone)
Primary Outcome Measure Information:
Title
Evaluation of Device and/or Procedure Related Adverse Event(s)
Time Frame
At 24-months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: One cervical spine level between C3 and C7 which requires surgical treatment for intractable cervical radiculopathy and/or myelopathy demonstrated by herniated disc, and/or osteophyte formation leading to nerve root and/or spinal cord compression confirmed by patient history (e.g. neck and/or arm pain), functional and/or neurological deficit (e.g. numbness, weakness, diminished or pathologic reflexes, gait disturbances, etc.) and radiographic studies (e.g. CT, MRI, x-rays, etc.). Unresponsive to conservative care over a period of at least 6 weeks Neck Disability Index score ≥ 15/50 (30%) Willing and able to comply with the requirements of the protocol including follow-up requirements and to sign a study specific informed consent Exclusion Criteria: More than 1 level requiring surgical treatment for intractable cervical radiculopathy and/or myelopathy. Active local (at the proposed surgical site) or systemic infection Prior anterior neck surgery at any level. Prior posterior cervical spine surgery at the index level except posterior decompressive surgery where the posterior elements are preserved. Currently undergoing treatment for disease of the thoracic or lumbar spine. Axial neck pain as the primary diagnosis, without evidence of neural compression Significant cervical anatomical deformity Any anatomical consideration which in the investigators opinion would make the anterior cervical approach excessively risky or impossible Severe obesity defined as a Body Mass Index (BMI) > 40 Instability on AP, lateral neutral or flex/ext images: ≥2mm translation relative to the adjacent segment, and/or ≥ 11 degrees relative to adjacent segments Central disc height ≤ 2mm Advanced spondylosis (i.e. facet joints degeneration, anterior or posterior bridging of the interspace or lack of motion on the pre-operative flexion/extension x-rays) Severe cervical myelopathy as indicated by: Signs and/or symptoms > 6months duration, Nurick's Classification grades IV or V, and/or Myelomalacia as evidence on a MRI Metabolic bone disease such as osteoporosis to a degree that spinal instrumentation is contra-indicated (Males over 55 years of age, females over 50 years of age and/or subjects that in the investigators opinion are medical indicative of osteoporosis (e.g. early menopause, steroid use, etc.) are required to have a DEXA scan; If the DEXA scan is ≤ -2.5t in the spine, the patient must be excluded) Allergy to any component of the device (titanium, polycarbonated polyurethane, polyethylene terephthalate, or ethylene oxide residuals) Chronic steroid or other medication use that may interfere with bony/soft tissue healing History of endocrine or metabolic disorders (e.g. Paget's disease) known to effect bone and mineral metabolism Autoimmune diseases e.g., ankylosing spondylitis, rheumatoid arthritis, etc. Insulin dependent diabetes mellitus Active malignancy Currently pregnant or considering becoming pregnant during the follow-up period Advanced emphysema, Alzheimer's disease or other medical conditions that would interfere with patient self-assessment of function, pain or quality of life Medical condition (e.g. unstable cardiac disease, end-stage cancer) that may result in patient death prior to study completion Chemical dependency (e.g. alcohol or narcotic addiction) problem that may interfere with study requirements Mental incompetence as determined by the Investigator which may effect participation in the study Incarcerated Involved in any current or pending litigation relating to a spinal condition Concurrently participating in any other investigational study Anatomy (e.g. endplate dimensions) at the index level not consistent with the dimensions of the implants available (e.g. based on pre-operative radiographic evaluations and templates in the surgical technique manual).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Scott L Blumenthal, M.D.
Organizational Affiliation
Texas Back Institute
Official's Role
Study Director
Facility Information:
Facility Name
University of California Davis
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States
Facility Name
Boulder Neurosurgical Associates
City
Boulder
State/Province
Colorado
ZIP/Postal Code
80304
Country
United States
Facility Name
University of South Florida
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Facility Name
Spine Institute of Louisiana
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71101
Country
United States
Facility Name
Brain and Spine Specialist
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21215
Country
United States
Facility Name
Cooper University Neurological Institute
City
Camden
State/Province
New Jersey
ZIP/Postal Code
08103
Country
United States
Facility Name
University of Rochester Medical Center
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
Triangle Orthopaedics Associates, P.A.
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27704
Country
United States
Facility Name
University of Pennsylvania, Department of Neurosurgery
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
East Tennessee Brain and Spine Center
City
Johnson City
State/Province
Tennessee
ZIP/Postal Code
37604
Country
United States
Facility Name
Texas Back Institute
City
Plano
State/Province
Texas
ZIP/Postal Code
75093
Country
United States
Facility Name
The San Antonio Orthopaedic Group
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78216
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Advent™ Cervical Disc Versus ACDF for Treatment of One Level Degenerative Disc Disease (IDE Study)

We'll reach out to this number within 24 hrs